SHELTON, Conn., June 13, 2017 /PRNewswire/ -- NanoViricides,
Inc., (NYSE MKT: NNVC) (the "Company"), a pioneer in developing
anti-viral nanomedicine drugs, reports that its CEO, Eugene Seymour, MD, MPH., will describe the
Company's progress towards human clinical trials stage at the 2017
Marcum Investor Conference. The Conference is being held on
Thursday, June15th, 2017, at the Grand Hyatt Hotel in
New York City. Dr. Seymour's talk
is scheduled for 11:30am.
The Company has recently reported that its drug candidates for
topical treatment of shingles were almost five times more effective
compared to acyclovir in cell culture studies. Moreover, no
cytotoxicity was observed at any of the doses tested for the
Company's drug candidates.
The Company has previously reported that treatment with certain
herpecide drug candidates led to complete survival of small animals
lethally infected with the aggressive and neurotropic HSV-1 strain
H129c, wherein all of the untreated animals died. Those animal
studies also reproducibly demonstrated dramatic improvements in
clinical symptoms associated with herpes simplex virus infection.
HSV-1 causes herpes labialis or "cold sores", and is also
linked to Alzheimer's disease.
The Company has expanded its HerpeCideā¢ program into development
of topical treatments for (a) herpes labialis (HSV-1), (b) genital
herpes (HSV-2), (c) shingles (VZV), and (d) herpes keratitis. Of
these, the shingles treatment program is currently the most
advanced and is rapidly moving towards clinical candidate
selection.
There is no animal model for shingles because the causative
virus, VZV (aka human herpesvirus-3 or HHV-3), does not infect
animals. A model based ex vivo human skin patch infection by
VZV has been developed by Dr. Jennifer
Moffat at SUNY Upstate Medical
University in Syracuse, NY.
As previously reported, the Company's nanoviricides are currently
being tested for their antiviral effects in this human skin model.
The Company believes that its drug candidates should show
effectiveness in this model, given the strong efficacy observed in
the cell culture model.
The Company believes that its shingles treatment program is
moving more rapidly towards human clinical trials compared to the
HSV-1 herpes labialis treatment program. The Company is working on
scaling up the production of the drug candidates for both of these
programs to the quantities needed for Safety and toxicology
studies, as well as for initial human clinical trials, under
appropriate guidelines.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricideĀ® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
that are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission.. Although it is not possible to
predict or identify all such factors, they may include the
following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-ceo-to-present-information-on-its-topical-shingles-treatment-at-the-2017-marcum-investor-conference-in-new-york-city-300472841.html
SOURCE NanoViricides, Inc.